Cardiovascular disease in Alpha 1 antitrypsin deficiency: an observational study assessing the role of neutrophil proteinase activity and the suitability of validated screening tools.
Alpha 1 anti-trypsin deficiency
Arterial stiffness
Cardiovascular disease
Chronic obstructive pulmonary disease
Emphysema
Neutrophils
Risk assessment
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
21 Mar 2024
21 Mar 2024
Historique:
received:
26
04
2023
accepted:
03
03
2024
medline:
22
3
2024
pubmed:
22
3
2024
entrez:
22
3
2024
Statut:
epublish
Résumé
Alpha 1 Antitrypsin Deficiency (AATD) is a rare, inherited lung disease which shares features with Chronic Obstructive Pulmonary Disease (COPD) but has a greater burden of proteinase related tissue damage. These proteinases are associated with cardiovascular disease (CVD) in the general population. It is unclear whether patients with AATD have a greater risk of CVD compared to usual COPD, how best to screen for this, and whether neutrophil proteinases are implicated in AATD-associated CVD. This study had three aims. To compare CVD risk in never-augmented AATD patients to non-AATD COPD and healthy controls (HC). To assess relationships between CVD risk and lung physiology. To determine if neutrophil proteinase activity was associated with CVD risk in AATD. Cardiovascular risk was assessed by QRISK2® score and aortic stiffness measurements using carotid-femoral (aortic) pulse wave velocity (aPWV). Medical history, computed tomography scans and post-bronchodilator lung function parameters were reviewed. Systemic proteinase 3 activity was measured. Patients were followed for 4 years, to assess CVD development. 228 patients with AATD, 50 with non-AATD COPD and 51 healthy controls were recruited. In all COPD and HC participants, QRISK2® and aPWV gave concordant results (with both measures either high or in the normal range). This was not the case in AATD. Once aPWV was adjusted for age and smoking history, aPWV was highest and QRISK2® lowest in AATD patients compared to the COPD or HC participants. Higher aPWV was associated with impairments in lung physiology, the presence of emphysema on CT scan and proteinase 3 activity following adjustment for age, smoking status and traditional CVD risk factors (using QRISK2® scores) in AATD. There were no such relationships with QRISK2® in AATD. AATD patients with confirmed CVD at four-year follow up had a higher aPWV but not QRISK2® at baseline assessment. aPWV measured CVD risk is elevated in AATD. This risk is not captured by QRISK2®. There is a relationship between aPWV, lung disease and proteinase-3 activity. Proteinase-driven breakdown of elastin fibres in large arteries and lungs is a putative mechanism and forms a potential therapeutic target for CVD in AATD.
Sections du résumé
BACKGROUND
BACKGROUND
Alpha 1 Antitrypsin Deficiency (AATD) is a rare, inherited lung disease which shares features with Chronic Obstructive Pulmonary Disease (COPD) but has a greater burden of proteinase related tissue damage. These proteinases are associated with cardiovascular disease (CVD) in the general population. It is unclear whether patients with AATD have a greater risk of CVD compared to usual COPD, how best to screen for this, and whether neutrophil proteinases are implicated in AATD-associated CVD. This study had three aims. To compare CVD risk in never-augmented AATD patients to non-AATD COPD and healthy controls (HC). To assess relationships between CVD risk and lung physiology. To determine if neutrophil proteinase activity was associated with CVD risk in AATD. Cardiovascular risk was assessed by QRISK2® score and aortic stiffness measurements using carotid-femoral (aortic) pulse wave velocity (aPWV). Medical history, computed tomography scans and post-bronchodilator lung function parameters were reviewed. Systemic proteinase 3 activity was measured. Patients were followed for 4 years, to assess CVD development.
RESULTS
RESULTS
228 patients with AATD, 50 with non-AATD COPD and 51 healthy controls were recruited. In all COPD and HC participants, QRISK2® and aPWV gave concordant results (with both measures either high or in the normal range). This was not the case in AATD. Once aPWV was adjusted for age and smoking history, aPWV was highest and QRISK2® lowest in AATD patients compared to the COPD or HC participants. Higher aPWV was associated with impairments in lung physiology, the presence of emphysema on CT scan and proteinase 3 activity following adjustment for age, smoking status and traditional CVD risk factors (using QRISK2® scores) in AATD. There were no such relationships with QRISK2® in AATD. AATD patients with confirmed CVD at four-year follow up had a higher aPWV but not QRISK2® at baseline assessment.
CONCLUSION
CONCLUSIONS
aPWV measured CVD risk is elevated in AATD. This risk is not captured by QRISK2®. There is a relationship between aPWV, lung disease and proteinase-3 activity. Proteinase-driven breakdown of elastin fibres in large arteries and lungs is a putative mechanism and forms a potential therapeutic target for CVD in AATD.
Identifiants
pubmed: 38515138
doi: 10.1186/s13023-024-03124-x
pii: 10.1186/s13023-024-03124-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
130Informations de copyright
© 2024. The Author(s).
Références
Crossley D, Stockley R, Sapey E. Alpha-1 antitrypsin deficiency and accelerated aging: a new model for an old disease? Drugs Aging. 2019;36(9):823–40.
doi: 10.1007/s40266-019-00684-7
pubmed: 31179525
Stockley RA, Edgar RG, Pillai A, Turner AM. Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management? Int J Chron Obstruct Pulmon Dis. 2016;11:1745–56.
doi: 10.2147/COPD.S111508
pubmed: 27536086
pmcid: 4976906
Butler A, Walton GM, Sapey E. Neutrophilic inflammation in the pathogenesis of chronic obstructive pulmonary disease. COPD. 2018;15(4):392–404.
doi: 10.1080/15412555.2018.1476475
pubmed: 30064276
Stockley RA, Parr DG, Piitulainen E, Stolk J, Stoel BC, Dirksen A. Therapeutic efficacy of alpha-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry. Respir Res. 2010;11:136.
doi: 10.1186/1465-9921-11-136
pubmed: 20920370
pmcid: 2964614
Sapey E, Yonel Z, Edgar R, Parmar S, Hobbins S, Newby P, et al. The clinical and inflammatory relationships between periodontitis and chronic obstructive pulmonary disease. J Clin Periodontol. 2020;47(9):1040–52.
doi: 10.1111/jcpe.13334
pubmed: 32567697
Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther Adv Respir Dis. 2018;12(1753-4666 (Electronic)):1753465817750524.
pubmed: 29355081
pmcid: 5937157
Pagliaroli E, Mohan D, Padmanaban V, Palange P, Elkin S, Polkey MI. Elevated QRISK2 score in patients hospitalized for acute exacerbation of COPD versus stable COPD outpatients. Int J Cardiol. 2015;179:312–4.
doi: 10.1016/j.ijcard.2014.11.065
pubmed: 25464473
Hippisley-Cox J, Coupland C, Robson J, Brindle P. Derivation, validation, and evaluation of a new QRISK model to estimate lifetime risk of cardiovascular disease: cohort study using QResearch database. BMJ. 2010;341: c6624.
doi: 10.1136/bmj.c6624
pubmed: 21148212
pmcid: 2999889
Nishijima T, Nakayama Y, Tsumura K, Yamashita N, Yoshimaru K, Ueda H, et al. Pulsatility of ascending aortic blood pressure waveform is associated with an increased risk of coronary heart disease. Am J Hypertens. 2001;14(5):469–73.
doi: 10.1016/S0895-7061(00)01288-7
pubmed: 11368469
Authors/Task Force M, Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34(28):2159–219.
Stone IS, Khanji MJ, James WY, Balawon A, Boubertakh R, John L, et al. P21 The applicability of current cardiovascular risk scores and cardiovascular surrogates in chronic obstructive pulmonary disease: a case-control study. Thorax. 2015;70(Suppl 3):A85.
doi: 10.1136/thoraxjnl-2015-207770.158
Sabit R, Bolton CE, Edwards PH, Pettit RJ, Evans WD, McEniery CM, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(12):1259–65.
doi: 10.1164/rccm.200701-067OC
pubmed: 17363772
McAllister DA, Maclay JD, Mills NL, Mair G, Miller J, Anderson D, et al. Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176(12):1208–14.
doi: 10.1164/rccm.200707-1080OC
pubmed: 17885263
pmcid: 2176105
Franciosi AN, Alkhunaizi MA, Woodsmith A, Aldaihani L, Alkandari H, Lee SE, et al. Alpha-1 antitrypsin deficiency and tobacco smoking: exploring risk factors and smoking cessation in a registry population. COPD J Chronic Obstruct Pulmonary Dis. 2021;18(1):76–82.
doi: 10.1080/15412555.2020.1864725
Dahl M, Tybjaerg-Hansen A, Sillesen H, Jensen G, Steffensen R, Nordestgaard BG. Blood pressure, risk of ischemic cerebrovascular and ischemic heart disease, and longevity in alpha(1)-antitrypsin deficiency: the Copenhagen City Heart Study. Circulation. 2003;107(5):747–52.
doi: 10.1161/01.CIR.0000049642.20484.5D
pubmed: 12578879
Fisk M, Cheriyan J, Mohan D, McEniery CM, Forman J, Cockcroft JR, et al. Vascular inflammation and aortic stiffness: potential mechanisms of increased vascular risk in chronic obstructive pulmonary disease. Respir Res. 2018;19(1):100.
doi: 10.1186/s12931-018-0792-1
pubmed: 29793484
pmcid: 5968523
Vizzardi E, Corda L, Pezzali N, Roca E, Pini L, D’Aloia A, et al. Elastic properties of the ascending aorta in patients with alpha1-antitrypsin deficiency (Z homozygotes). Heart. 2012;98(18):1354–8.
doi: 10.1136/heartjnl-2012-302144
pubmed: 22851685
Fawcett KA, Song K, Qian G, Farmaki AE, Packer R, John C, et al. Pleiotropic associations of heterozygosity for the SERPINA1 Z allele in the UK Biobank. ERJ Open Res. 2021;7(2):00049–2021.
doi: 10.1183/23120541.00049-2021
pubmed: 33981765
pmcid: 8107350
Miravitlles M, Turner AM, Torres-Duran M, Tanash H, Rodríguez-García C, López-Campos JL, et al. Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry. Respir Res. 2022;23(1):352.
doi: 10.1186/s12931-022-02275-4
pubmed: 36527073
pmcid: 9756677
Winther SV, Ahmed D, Al-Shuweli S, Landt EM, Nordestgaard BG, Seersholm N, et al. Severe α
doi: 10.1186/s12931-022-01973-3
pubmed: 35264159
pmcid: 8905778
Duckers JM, Shale DJ, Stockley RA, Gale NS, Evans BAJ, Cockcroft JR, et al. Cardiovascular and musculskeletal co-morbidities in patients with alpha 1 antitrypsin deficiency. Respir Res. 2010;11(1):173.
doi: 10.1186/1465-9921-11-173
pubmed: 21138571
pmcid: 3004850
Dako F, Zhao H, Mulvenna A, Gupta S, Simpson S, Kueppers F. Relationship between Alpha-1-antitrypsin deficiency and ascending aortic distention. Eur Respir J. 2019;54:PA5391.
Takahashi T, Hiasa Y, Ohara Y, Miyazaki S-i, Ogura R, Suzuki N, et al. Relationship of admission neutrophil count to microvascular injury, left ventricular dilation, and long-term outcome in patients treated with primary angioplasty for acute myocardial infarction. Circul J. 2008;72(6):867–72.
doi: 10.1253/circj.72.867
Kaya MG, Yalcin R, Okyay K, Poyraz F, Bayraktar N, Pasaoglu H, et al. Potential role of plasma myeloperoxidase level in predicting long-term outcome of acute myocardial infarction. Tex Heart Inst J. 2012;39(1526-6702 (Electronic)):500–6.
pubmed: 22949765
pmcid: 3423276
Ong K-L, Wu L, Januszewski AS, O’Connell R, Xu A, Scott RS, et al. The relationship of neutrophil elastase and proteinase 3 with risk factors, and chronic complications in type 2 diabetes: a fenofibrate intervention and event lowering in diabetes (FIELD) sub-study. Diab Vasc Dis Res. 2021;18(4):14791641211032548.
doi: 10.1177/14791641211032547
pubmed: 34275349
pmcid: 8481737
Newby PR, Crossley D, Crisford H, Stockley JA, Mumford RA, Carter RI, et al. A specific proteinase 3 activity footprint in alpha1-antitrypsin deficiency. ERJ Open Res. 2019;5(3).
Sapey E. Neutrophil modulation in alpha-1 antitrypsin deficiency. Chronic Obstr Pulm Dis. 2020;7(3):247–59.
pubmed: 32697897
pmcid: 7857711
Jasper AE, McIver WJ, Sapey E, Walton GM. Understanding the role of neutrophils in chronic inflammatory airway disease. F1000Res. 2019;8.
Fähndrich S, Biertz F, Karch A, Kleibrink B, Koch A, Teschler H, et al. Cardiovascular risk in patients with alpha-1-antitrypsin deficiency. Respir Res. 2017;18(1):171.
doi: 10.1186/s12931-017-0655-1
pubmed: 28915894
pmcid: 5602961
Khanji MY, Stone IS, Boubertakh R, Cooper JA, Barnes NC, Petersen SE. Chronic obstructive pulmonary disease as a predictor of cardiovascular risk: a case-control study. COPD. 2020;17(1):81–9.
doi: 10.1080/15412555.2019.1694501
pubmed: 31833441
Mitu O, Crisan A, Redwood S, Cazacu-Davidescu I-E, Mitu I, Costache I-I, et al. The relationship between cardiovascular risk scores and several markers of subclinical atherosclerosis in an asymptomatic population. J Clin Med. 2021;10(5).
Wagenseil JE, Mecham RP. Elastin in large artery stiffness and hypertension. J Cardiovasc Transl Res. 2012;5(3):264–73.
doi: 10.1007/s12265-012-9349-8
pubmed: 22290157
pmcid: 3383658
Yasmin, McEniery CM, O’Shaughnessy KM, Harnett P, Arshad A, Wallace S, et al. Variation in the human matrix metalloproteinase-9 gene is associated with arterial stiffness in healthy individuals. Arterioscler Thromb Vasc Biol. 2006;26(8):1799–805.
doi: 10.1161/01.ATV.0000227717.46157.32
pubmed: 16709939
Bonaventura A, Montecucco F, Dallegri F, Carbone F, Lüscher TF, Camici GG, et al. Novel findings in neutrophil biology and their impact on cardiovascular disease. Cardiovasc Res. 2019;115(8):1266–85.
doi: 10.1093/cvr/cvz084
pubmed: 30918936
British TS. Guidelines for the measurement of respiratory function. Respir Med. 1994;88(3):165–94.
doi: 10.1016/S0954-6111(05)80346-4
Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324.
doi: 10.1183/09031936.00080312
pubmed: 22743675
pmcid: 3786581
Müller J, Oberhoffer R, Barta C, Hulpke-Wette M, Hager A. Oscillometric carotid to femoral pulse wave velocity estimated with the vicorder device. J Clin Hypertens. 2013;15(3):176–9.
doi: 10.1111/jch.12045
Sutton-Tyrrell K, Najjar SS, Boudreau RM, Venkitachalam L, Kupelian V, Simonsick EM, et al. Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation. 2005;111(25):3384–90.
doi: 10.1161/CIRCULATIONAHA.104.483628
pubmed: 15967850
Collins GS, Altman DG. Predicting the 10 year risk of cardiovascular disease in the United Kingdom: independent and external validation of an updated version of QRISK2. BMJ. 2012;344: e4181.
doi: 10.1136/bmj.e4181
pubmed: 22723603
pmcid: 3380799